SCHEMBL290175

SCHEMBL290175

CCOC(=O)C(O)c1ccccc1C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.45
PTGDR2 Q9Y5Y4 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
SLC6A2 P23975 4/20 0.42
SLC6A3 Q01959 3/20 0.42
SLC6A4 P31645 3/20 0.42
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 1/20 0.40
CASP1 P29466 1/20 0.40
HPGD P15428 2/20 0.39
NAAA Q02083 1/20 0.39
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2D6 P10635 1/20 0.38
CHRM1 P11229 1/20 0.38
CYP2C9 P11712 1/20 0.38
DRD1 P21728 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25188997 0.99 SLC6A2 (0.43) TSHRPTGDR2L3MBTL1SLC6A2SLC6A3
SCHEMBL11467456 0.86 PTGDR2 (0.43) TSHRPTGDR2SLC6A2SLC6A3SLC6A4
SCHEMBL2062805 0.84 PTGDR2 (0.41) TSHRPTGDR2SLC6A2SLC6A3SLC6A4
SCHEMBL1222346 0.84 PTGDR2 (0.41) TSHRPTGDR2SLC6A2SLC6A3SLC6A4
SCHEMBL2062415 0.84 PTGDR2 (0.41) TSHRPTGDR2SLC6A2SLC6A3SLC6A4
SCHEMBL7914136 0.83 PTGDR2 (0.40) TSHRPTGDR2SLC6A2SLC6A3SLC6A4
SCHEMBL7905925 0.82 PTGDR2 (0.40) TSHRPTGDR2SLC6A2SLC6A3SLC6A4
SCHEMBL3364418 0.82 PTGDR2 (0.38) TSHRPTGDR2SLC6A2SLC6A3SLC6A4
Bromide SCHEMBL17076630 0.82 SLC6A2 (0.34) TSHRPTGDR2L3MBTL1SLC6A2SLC6A3
Bromide SCHEMBL17076633 0.82 SLC6A2 (0.34) TSHRPTGDR2L3MBTL1SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10449173-B2 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions ALLERGAN SALES, LLC (US) 2019-10-22 US disclosed
EP-3287122-B1 DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS FOR TREATING OVERACTIVE BLADDERS. ALLERGAN SALES LLC (US) 2019-04-17 EP disclosed
EP-3287122-A1 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS Allergan Sales, LLC (US) 2018-02-28 EP disclosed
EP-2427172-B1 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS ALLERGAN SALES LLC (US) 2017-11-01 EP disclosed
US-20160128963-A1 METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS WATSON LABORATORIES, INC. 2016-05-12 US disclosed
US-9259388-B2 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions WATSON PHARMACEUTICALS, INC. (US) 2016-02-16 US disclosed
US-8920392-B2 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions WATSON LABORATORIES, INC. (US) 2014-12-30 US disclosed
US-20140046275-A1 Method for Treating Overactive Bladders and a Device for Storage and Administration of Topical Oxybutynin Compositions WATSON LABORATORIES, INC. (US) 2014-02-13 US disclosed
EP-2427172-A2 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS Watson Laboratories, Inc. (US) 2012-03-14 EP disclosed
WO-2010129498-A2 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS WATSON LABORATORIES, INC. (US) 2010-11-11 WO disclosed
US-20100286630-A1 Method For Treating Overactive Bladders And A Device For Storage And Administration Of Topical Oxybutynin Compositions WATSON LABORATORIES, INC. (US) 2010-11-11 US disclosed